Original ArticlesThrombolytic effect of lonomin V in a rabbit jugular vein thrombosis modelGuerrero, B.; Arocha-Piñango, C. L.; Pinto, M Alves; Müller, C. A.; Juan, A. Gil San; Amorim, S.; Perales, J.Author Information B. Guerrero, C. L. Arocha-Piñango and A. Gil San Juan are with the Instituto Venezolano de Investigaciones Científicas (IVIC), Venezuela; and B. Guerrero, M Alves Pinto, C. A. Müller, S. Amorim and J. Perales are with the Fundação Oswaldo Cruz, IOC, Brazil. (Received 16 March 2001; revised 30 May 2001: accepted 31 May 2001) Sponsorship: This work was supported by Brazilian Grant from CNPq, FAPERJ and PAPES/FIOCRUZ and Venezuelan Grant CONICIT and Instituto Venezolano de Investigaciones Científicas (IVIC). Address correspondence to Belsy Guerrero and Carmen Luisa Arocha-Piñango, Centro de Medicina Experimental, Instituto Venezolano de Investigaciones Científicas, P.O. Box 21827, Caracas 1020-A, Venezuela. Tel: +58 212 504 1180; fax: +58 212 504 1086; e-mail: firstname.lastname@example.org Blood Coagulation & Fibrinolysis: October 2001 - Volume 12 - Issue 7 - p 521-529 Buy Abstract Thrombolytic efficacy of lonomin V (LV), a protein isolated from Lonomia achelous caterpillars haemolymph, administered either as a single intravenous bolus or as a continuous infusion, was evaluated in a rabbit jugular vein thrombosis model, and compared with those of single-chain tissue-type plasminogen activator (sct-PA) and two-chain urokinase-type plasminogen activator (tcu-PA). As a bolus LV, at doses of 100 000 IU/kg body weight (bw) produced an activator-induced thrombolysis (AIL) of 50.94% ± 12.4 compared with 14.4% ± 10.8 for tcu-PA at the same dose. As a continuous infusion at doses of 200 000 IU/kg bw LV produced an AIL of 45.8%, whereas sct-PA and tcu-PA produced an AIL of 69.9 and 33.7%, respectively. Fibrinogen, plasminogen and α-2-antiplasmin levels decreased significantly with the higher doses of LV, sct-PA, and tcu-PA. Factor XIII levels were significantly reduced in a dose-dependent manner only with LV. In conclusion, LV produces a dose-dependent thrombolysis in combination with a decrease in factor XIII activity. © 2001 Lippincott Williams & Wilkins, Inc.